PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31596896-5 2019 RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity. Bexarotene 47-57 apolipoprotein E Mus musculus 196-200 33099295-3 2020 Bexarotene has been found to improve neurological function in mice in an ApoE-dependent manner, but the detailed mechanism is not fully clear. Bexarotene 0-10 apolipoprotein E Mus musculus 73-77 31596896-5 2019 RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity. Bexarotene 47-57 apolipoprotein E Mus musculus 276-280 29995422-1 2019 Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits. Bexarotene 0-10 apolipoprotein E Mus musculus 109-113 31055081-8 2019 Murine (m)BCEC isolated from 3xTg AD mice treated with Bex revealed elevated expression of APOE and ABCA1. Bexarotene 55-58 apolipoprotein E Mus musculus 91-95 27235741-0 2017 Bexarotene protects against traumatic brain injury in mice partially through apolipoprotein E. Bexarotene 0-10 apolipoprotein E Mus musculus 77-93 28689412-2 2017 It has been suggested that bexarotene stimulates expression of apolipoprotein E (ApoE) leading to intracellular clearance of amyloid beta (Abeta). Bexarotene 27-37 apolipoprotein E Mus musculus 63-79 28689412-2 2017 It has been suggested that bexarotene stimulates expression of apolipoprotein E (ApoE) leading to intracellular clearance of amyloid beta (Abeta). Bexarotene 27-37 apolipoprotein E Mus musculus 81-85 27235741-10 2017 Taken together, bexarotene inhibits the inflammatory response as well as cell apoptosis and improves the neurological function of mice after TBI partially through apolipoprotein E. Bexarotene 16-26 apolipoprotein E Mus musculus 163-179 26175148-5 2016 We have previously shown that bexarotene reduces Abeta levels in AD mouse models and we have hypothesized that this effect requires ABCA1-mediated lipidation of ApoE. Bexarotene 30-40 apolipoprotein E Mus musculus 161-165 27051978-2 2016 Here we examine if the effect of bexarotene on RXR cistrome and transcriptomes depend on APOE isoform and Abeta deposition. Bexarotene 33-43 apolipoprotein E Mus musculus 89-93 27842487-7 2017 Administration of bexarotene facilitates intracellular Abeta clearance via RXR regulated apolipoprotein E (ApoE) production. Bexarotene 18-28 apolipoprotein E Mus musculus 89-105 27842487-7 2017 Administration of bexarotene facilitates intracellular Abeta clearance via RXR regulated apolipoprotein E (ApoE) production. Bexarotene 18-28 apolipoprotein E Mus musculus 107-111 26688581-2 2016 Bexarotene, a retinoid X receptor (RXR) agonist, has been reported to have potential beneficial effects on cognition by increasing brain apoE levels and lipidation. Bexarotene 0-10 apolipoprotein E Mus musculus 137-141 26688581-4 2016 Upon bexarotene treatment, levels of brain apoE and ATP-binding cassette sub-family A member 1 (ABCA1) were significantly increased in both mice. Bexarotene 5-15 apolipoprotein E Mus musculus 43-47 26688581-8 2016 Taken together, our results demonstrate that apoE-targeted treatment through the RXR pathway has a potential beneficial effect on synapses during aging; however, the therapeutic application of bexarotene requires extreme caution due to its toxic side effects. Bexarotene 193-203 apolipoprotein E Mus musculus 45-49 26175148-4 2016 ApoE and ABCA1 are induced by the action of the RXR agonist, bexarotene. Bexarotene 61-71 apolipoprotein E Mus musculus 0-4 26175148-14 2016 These data indicate that ABCA1-induced lipidation of ApoE is necessary for the ability of bexarotene to clear hippocampal soluble Abeta and ameliorate cognitive deficits. Bexarotene 90-100 apolipoprotein E Mus musculus 53-57 25217640-1 2014 Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation. Bexarotene 31-41 apolipoprotein E Mus musculus 218-234 25630951-0 2015 Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis. Bexarotene 24-34 apolipoprotein E Mus musculus 112-116 25777514-4 2015 Bexarotene (BEXA), an RXR agonist that increases ApoE expression and microglia phagocytosis has been proposed as a promising therapy for AD, resolving both the amyloid pathology and memory loss. Bexarotene 0-10 apolipoprotein E Mus musculus 49-53 25777514-4 2015 Bexarotene (BEXA), an RXR agonist that increases ApoE expression and microglia phagocytosis has been proposed as a promising therapy for AD, resolving both the amyloid pathology and memory loss. Bexarotene 12-16 apolipoprotein E Mus musculus 49-53 26085639-6 2015 We report that the omega-3 fatty acid docosahexaenoic acid (DHA), in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces soluble forms of Abeta, and abrogates release of pro-inflammatory cytokines and mediators both in vitro and in a mouse model of AD. Bexarotene 86-96 apolipoprotein E Mus musculus 151-155 25217640-1 2014 Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation. Bexarotene 31-41 apolipoprotein E Mus musculus 236-240 25217640-1 2014 Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation. Bexarotene 31-41 apolipoprotein E Mus musculus 276-280 24599963-7 2014 These effects on modulating apoE are comparable with the effects recently reported for the RXR agonist bexarotene. Bexarotene 103-113 apolipoprotein E Mus musculus 28-32 25164224-13 2014 CONCLUSION: Bexarotene treatment could attenuate arteriosclerosis progression in STZ induced diabetic apoE(-/-) mice, the underlying mechanism might be related to suppressing oxidative stress and decreasing blood glucose level and improving lipids metabolism. Bexarotene 12-22 apolipoprotein E Mus musculus 102-106 24599963-9 2014 Both bexarotene and 9-cis-RA promote the lipidation status of apoE, in which 9-cis-RA promotes a stronger effect and exhibits less cytotoxicity compared with bexarotene. Bexarotene 158-168 apolipoprotein E Mus musculus 62-66 24599963-10 2014 Importantly, we showed that oral administration of bexarotene and 9-cis-RA significantly increases apoE, ABCA1, and ABCG1 levels in mouse brains. Bexarotene 51-61 apolipoprotein E Mus musculus 99-103 24849361-4 2014 In the present study, we investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apoE, ABCA1, and ABCG1 in young, naive apoE3- and apoE4-targeted replacement mice and assessed the extent to which this reverses the apoE4-driven pathological phenotype. Bexarotene 69-79 apolipoprotein E Mus musculus 110-114 24599963-9 2014 Both bexarotene and 9-cis-RA promote the lipidation status of apoE, in which 9-cis-RA promotes a stronger effect and exhibits less cytotoxicity compared with bexarotene. Bexarotene 5-15 apolipoprotein E Mus musculus 62-66 24047423-4 2013 Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits. Bexarotene 77-87 apolipoprotein E Mus musculus 229-233 24047423-4 2013 Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits. Bexarotene 89-98 apolipoprotein E Mus musculus 229-233 23601557-11 2013 Administration of the RXR agonist bexarotene increased ISF apoE levels while ISF Abeta levels were decreased. Bexarotene 34-44 apolipoprotein E Mus musculus 59-63 23764200-4 2013 Drugs that activate RXRs, including bexarotene, can increase APOE and ABCA1 production, and have been shown to decrease the Abeta burden and improve cognition in mouse models of Abeta amyloidosis. Bexarotene 36-46 apolipoprotein E Mus musculus 61-65 22323736-3 2012 Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced clearance of soluble Abeta within hours in an apoE-dependent manner. Bexarotene 39-49 apolipoprotein E Mus musculus 140-144